• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血小板衍生生长因子受体-β和血管内皮生长因子受体-2在血管肉瘤患者中的预后意义截然不同。

Contrasting prognostic implications of platelet-derived growth factor receptor-β and vascular endothelial growth factor receptor-2 in patients with angiosarcoma.

机构信息

Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.

出版信息

Ann Surg Oncol. 2011 Oct;18(10):2841-50. doi: 10.1245/s10434-011-1640-4. Epub 2011 Mar 16.

DOI:10.1245/s10434-011-1640-4
PMID:21409488
Abstract

BACKGROUND

Angiosarcoma is an extremely rare tumor among sarcomas and comprises a heterogeneous group of high-grade vascular malignancies. Our study aimed to examine the correlations between 6 immunohistochemical biomarkers-stem cell factor receptor (KIT), platelet-derived growth factor receptor (PDGFR)-α, PDGFR-β, vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, and VEGFR-3-and overall survival (OS) in patients with angiosarcomas.

METHODS

Immunohistochemical analyses for the 6 biomarkers were performed by using tumor specimens obtained from 34 patients with angiosarcomas. Correlations between biomarkers were examined by Fisher's exact test. For each biomarker, the correlation between the immunohistochemical score and OS was examined by the log-rank test and Cox regression analysis.

RESULTS

The percentages of angiosarcoma patients with positive expressions (immunohistochemical score > 0) of KIT, PDGFR-α, PDGFR-β, VEGFR-1, VEGFR-2, and VEGFR-3 were 14.7%, 11.8%, 88.2%, 61.8%, 94.1%, and 100.0%, respectively. No statistically significant correlations between any 2 biomarkers were observed. Cox regression analysis demonstrated a significant positive correlation between short OS and the immunohistochemical score for PDGFR-β and between long OS and the immunohistochemical score for VEGFR-2.

CONCLUSION

Increased expression of PDGFR-β may be a statistically significant prognostic factor for poor OS, while increased expression of VEGFR-2 may be a favorable prognostic factor for patients with angiosarcoma.

摘要

背景

血管肉瘤是肉瘤中一种极其罕见的肿瘤,由一组异质性的高级别血管恶性肿瘤组成。我们的研究旨在探讨 6 种免疫组织化学标志物——干细胞因子受体(KIT)、血小板衍生生长因子受体(PDGFR)-α、PDGFR-β、血管内皮生长因子受体(VEGFR)-1、VEGFR-2 和 VEGFR-3——与血管肉瘤患者总生存(OS)之间的相关性。

方法

采用免疫组织化学分析法对 34 例血管肉瘤患者的肿瘤标本进行 6 种标志物的检测。采用 Fisher 确切概率法对标志物进行相关性分析。采用 log-rank 检验和 Cox 回归分析,对每种标志物的免疫组织化学评分与 OS 之间的相关性进行检验。

结果

KIT、PDGFR-α、PDGFR-β、VEGFR-1、VEGFR-2 和 VEGFR-3 阳性表达(免疫组织化学评分>0)的血管肉瘤患者比例分别为 14.7%、11.8%、88.2%、61.8%、94.1%和 100.0%。未观察到任何 2 种标志物之间存在统计学显著相关性。Cox 回归分析显示,PDGFR-β 免疫组织化学评分与短 OS 呈显著正相关,VEGFR-2 免疫组织化学评分与长 OS 呈显著正相关。

结论

PDGFR-β 表达增加可能是 OS 不良的统计学显著预后因素,而 VEGFR-2 表达增加可能是血管肉瘤患者的有利预后因素。

相似文献

1
Contrasting prognostic implications of platelet-derived growth factor receptor-β and vascular endothelial growth factor receptor-2 in patients with angiosarcoma.血小板衍生生长因子受体-β和血管内皮生长因子受体-2在血管肉瘤患者中的预后意义截然不同。
Ann Surg Oncol. 2011 Oct;18(10):2841-50. doi: 10.1245/s10434-011-1640-4. Epub 2011 Mar 16.
2
Clinically relevant biomarkers to select patients for targeted inhibitor therapy after resection of hepatocellular carcinoma.用于选择接受肝癌切除术后靶向抑制剂治疗的患者的临床相关生物标志物。
Ann Surg Oncol. 2011 Nov;18(12):3384-90. doi: 10.1245/s10434-011-1775-3. Epub 2011 May 18.
3
Autocrine and paracrine roles of VEGF/VEGFR-2 and VEGF-C/VEGFR-3 signaling in angiosarcomas of the scalp and face.血管内皮生长因子(VEGF)/血管内皮生长因子受体-2(VEGFR-2)和血管内皮生长因子-C(VEGF-C)/血管内皮生长因子受体-3(VEGFR-3)信号在头皮和面部血管肉瘤中的自分泌和旁分泌作用。
Hum Pathol. 2010 Mar;41(3):407-14. doi: 10.1016/j.humpath.2009.08.021. Epub 2009 Nov 13.
4
Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma.血管内皮生长因子C和血管内皮生长因子受体3在非小细胞肺癌患者中的临床意义
Cancer. 2003 Jan 15;97(2):457-64. doi: 10.1002/cncr.11073.
5
Clinical significance of vascular endothelial growth factor-C and vascular endothelial growth factor receptor 3 in patients with T1 lung adenocarcinoma.血管内皮生长因子-C和血管内皮生长因子受体3在T1期肺腺癌患者中的临床意义
Cancer. 2005 Oct 15;104(8):1668-77. doi: 10.1002/cncr.21366.
6
Analysis of vascular gene expression in arthritic synovium by laser-mediated microdissection.通过激光介导的显微切割分析关节炎滑膜中的血管基因表达。
Arthritis Rheum. 2007 Apr;56(4):1094-105. doi: 10.1002/art.22450.
7
Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.在晚期或转移性实体瘤患者中开展的一项关于替拉替尼(一种血管内皮生长因子受体2和3、血小板衍生生长因子受体β以及c-Kit的酪氨酸激酶抑制剂)的I期剂量递增研究。
J Clin Oncol. 2009 Sep 1;27(25):4169-76. doi: 10.1200/JCO.2008.18.8193. Epub 2009 Jul 27.
8
Cell surface receptor expression patterns in osteosarcoma.骨肉瘤细胞表面受体表达模式。
Cancer. 2012 Feb 1;118(3):740-9. doi: 10.1002/cncr.26339. Epub 2011 Jul 12.
9
Clinical impact of phosphorylated signal transducer and activator of transcription 3, epidermal growth factor receptor, p53, and vascular endothelial growth factor receptor 1 expression in resected adenocarcinoma of lung by using tissue microarray.应用组织微阵列检测磷酸化信号转导和转录激活因子 3、表皮生长因子受体、p53 和血管内皮生长因子受体 1 在切除的肺腺癌中的表达对临床的影响。
Cancer. 2010 Feb 1;116(3):676-85. doi: 10.1002/cncr.24748.
10
Vascular endothelial growth factor receptor expression as a prognostic marker for survival in colorectal cancer.血管内皮生长因子受体表达作为结直肠癌生存的预后标志物
Jpn J Clin Oncol. 2009 Sep;39(9):595-600. doi: 10.1093/jjco/hyp066. Epub 2009 Jun 17.

引用本文的文献

1
Angiosarcoma: a systematic review of biomarkers in diagnosis, prognosis, and therapeutic strategies.血管肉瘤:关于诊断、预后及治疗策略中生物标志物的系统综述
Front Oncol. 2025 Jul 1;15:1623327. doi: 10.3389/fonc.2025.1623327. eCollection 2025.
2
Environmental Pollutants, Occupational Exposures, and Liver Disease.环境污染物、职业暴露与肝脏疾病
Semin Liver Dis. 2025 Jun;45(2):148-166. doi: 10.1055/a-2540-2861. Epub 2025 Mar 21.
3
PDGFR-β fibroblasts deteriorate survival in human solid tumors: a meta-analysis.PDGFR-β 成纤维细胞恶化人类实体瘤的生存:一项荟萃分析。
Aging (Albany NY). 2021 May 3;13(10):13693-13707. doi: 10.18632/aging.202952.
4
Candidate Biomarkers for Specific Intraoperative Near-Infrared Imaging of Soft Tissue Sarcomas: A Systematic Review.软组织肉瘤特定术中近红外成像的候选生物标志物:一项系统评价
Cancers (Basel). 2021 Feb 1;13(3):557. doi: 10.3390/cancers13030557.
5
A single-arm confirmatory trial of pazopanib in patients with paclitaxel-pretreated primary cutaneous angiosarcoma: Japan Clinical Oncology Group study (JCOG1605, JCOG-PCAS protocol).紫杉醇预处理的原发性皮肤血管肉瘤患者中帕唑帕尼的单臂确证性试验:日本临床肿瘤学组研究(JCOG1605,JCOG-PCAS 方案)。
BMC Cancer. 2020 Jul 13;20(1):652. doi: 10.1186/s12885-020-07136-1.
6
The prognostic value of pretreatment inflammatory biomarkers in primary angiosarcoma.原发性血管肉瘤中预处理炎症生物标志物的预后价值
Cancer Manag Res. 2019 Aug 22;11:7981-7989. doi: 10.2147/CMAR.S219237. eCollection 2019.
7
Radiobrominated benzimidazole-quinoline derivatives as Platelet-derived growth factor receptor beta (PDGFRβ) imaging probes.放射性标记的苯并咪唑-喹啉衍生物作为血小板衍生生长因子受体β(PDGFRβ)成像探针。
Sci Rep. 2018 Jul 10;8(1):10369. doi: 10.1038/s41598-018-28529-0.
8
Clinical Usefulness of the Platelet-to Lymphocyte Ratio in Patients with Angiosarcoma of the Face and Scalp.血小板与淋巴细胞比值在头面部血管肉瘤患者中的临床应用价值。
Int J Mol Sci. 2017 Nov 13;18(11):2402. doi: 10.3390/ijms18112402.
9
Pazopanib treatment slows progression and stabilizes disease in patients with taxane-resistant cutaneous angiosarcoma.帕唑帕尼治疗可减缓紫杉烷耐药性皮肤血管肉瘤患者的疾病进展并稳定病情。
Med Oncol. 2016 Oct;33(10):116. doi: 10.1007/s12032-016-0831-z. Epub 2016 Sep 9.
10
Effects of inhibitors of vascular endothelial growth factor receptor 2 and downstream pathways of receptor tyrosine kinases involving phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin or mitogen-activated protein kinase in canine hemangiosarcoma cell lines.血管内皮生长因子受体2抑制剂以及涉及磷脂酰肌醇3激酶/蛋白激酶B/雷帕霉素哺乳动物靶点或丝裂原活化蛋白激酶的受体酪氨酸激酶下游通路对犬血管肉瘤细胞系的影响
Can J Vet Res. 2016 Jul;80(3):209-16.